Probiotics for Preventing Graft-versus-Host Disease

"Allogeneic Hematopoietic Stem Cell Transplantation is considered safe, as it has advanced to Phase 3 in clinical trials. This means that there is efficacy data supporting the intervention and multiple rounds of safety data."

"The age range for this particular study is 2 to 25. There are 695 other clinical trials underway for individuals under 18 and 3,335 studies available for patients over 65."

"Allogeneic Hematopoietic Stem Cell Transplantation is often used to improve gut health, but it can also be a helpful form of therapy for treating vulvovaginitis, chemotherapy side effects, and bacterial infections."

"This trial, as documented on clinicaltrials.gov, is no longer actively recruiting patients. It was initially posted on April 30th, 2018 but has not been updated since July 20th, 2022. Although this study is closed to new participants, there are 3749 other trials that remain open and are currently looking for volunteers."

"This study is no longer enrolling participants. It was initially posted on April 30th, 2018 and last updated on July 20th, 2022. If you are seeking other trials, there are 3747 active clinical studies for lymphoma patients and 2 trials for Allogeneic Hematopoietic Stem Cell Transplantation recruiting right now."

"41 patients are currently enrolled in this study, with locations including the Alberta Children's Hospital in Calgary, UCSF Benioff Children's Hospital Oakland in Oakland, Helen DeVos Children's Hospital at Spectrum Health in Grand Rapids, as well as 41 other sites."

"At this time, there are two ongoing clinical trials involving allogeneic hematopoietic stem cell transplantation. Of these, two are in Phase 3. Most of the trials for allogeneic hematopoietic stem cell transplantation are taking place in New york City; however, there are 51 total locations running such studies."

"This study is looking for 167 participants between the ages of 2 and 25 who have lymphoma. To be eligible, patients must also meet the following criteria: All clinical and laboratory studies, if applicable, must be obtained within 21 days prior to start of protocol therapy (repeat if necessary); protocol therapy must begin within 6 months of study enrollment; Patient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplant; Patients must have a Lansky (for patients =< 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of >="